Sugi Predict

Sugi Predict / Compounds / SCHEMBL2172162

SCHEMBL2172162

SCHEMBL2172162

COC(=O)CC1CN[C@H](C(=O)N2CCC(c3ccccc3)C2)[C@@H](C(=O)OC(C)(C)C)C1

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 15/20 0.61
▸ ERBB2 P04626 14/20 0.61
▸ MMP2 P08253 12/20 0.61
▸ MMP3 P08254 1/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TP53 P04637 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173751 0.93 ADAM10 (0.60) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3457440 0.89 ADAM10 (0.67) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2175263 0.82 ADAM10 (0.80) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL6025047 0.79 ADAM10 (0.53) ADAM10ERBB2MMP2LMNAALDH1A1
SCHEMBL2172167 0.76 ADAM10 (0.47) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3457447 0.76 ADAM10 (1.00) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2172539 0.76 ADAM10 (1.00) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3457457 0.76 ADAM10 (1.00) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2175825 0.76 ADAM10 (1.00) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2172969 0.75 BRD4 (0.34) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ADAM10 25/4885ERBB2 2986/4885MMP2 4/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.